Detalhe da pesquisa
1.
Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.
Diabetes Care
; 45(5): 1211-1218, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263432
2.
Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.
Diabetes Ther
; 12(5): 1325-1339, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33723769
3.
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
Diabetes Ther
; 11(1): 259-277, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31833042
4.
Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.
Diabetes Ther
; 10(6): 2183-2199, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31599391
5.
Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates.
Curr Med Res Opin
; 34(4): 601-611, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29292670
6.
Increased cost of illness among European patients with type 2 diabetes treated with insulin.
Curr Med Res Opin
; 33(1): 47-54, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27595332
7.
Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe.
Clin Exp Gastroenterol
; 9: 311-323, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27785086